SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic ...

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase ...

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple ...

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; ...

Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical ...

Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.

In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the ...